Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q2 2021 call → NOWe need to determine if management describes successive engagements of the same kind coming in at progressively larger size. Look for comparisons against own past, real and recurring, early stage. Scan transcript for mentions of deals, orders, contracts, projects, customers, sites, programs. Focus on size escalation. Key topics: card spend, loan growth, IB fees, AWM flows, branch expansion, acquisitions. But need specific "unit size" escalation. Search for phrases like "larger", "bigger", "record", "average size", "initial commitments", "follow-on". In the transcript, Jamie Dimon talks about acquisitions: "a string of pearls" but not about size escalation. He mentions "we are planning to be in all 48 contiguous states" - that's expansion, not unit size. Jeremy Barnum on card: "combined debit and credit spend was up 45% year on year and more importantly up 22% versus the more normal pre-COVID second quarter of 2019." That's volume, not unit size. On IB fees: "all-time record for IB fees, up 25% year on year" - but that's total fees, not average deal size. On AWM: "record long-term flows" - again total. On branches: "opened more than 200 new branches out of our goal of 400" - that's number of branches, not size per branch. On acquisitions: "we've done eight since December" - but no mention of each being larger. Look for any statement about average deal size or initial commitments being larger. Not present. There is mention of "record" but not about unit size escalation. Thus answer NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.